The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A pediatric phase I trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A Children’s Oncology Group Phase I Consortium Study.
T. R. Hummel
No relevant relationships to disclose
L. M. Wagner
No relevant relationships to disclose
C. H. Ahern
No relevant relationships to disclose
R. M. McGovern
No relevant relationships to disclose
M. M. Ames
No relevant relationships to disclose
R. J. Gilbertson
No relevant relationships to disclose
T. M. Horton
No relevant relationships to disclose
A. M. Ingle
No relevant relationships to disclose
B. Weigel
No relevant relationships to disclose
S. Blaney
No relevant relationships to disclose